Last reviewed · How we verify

NCT04819555: GENIALS

Frequency of SOD1 and C9orf72 Gene Mutations in French ALS

Completed Last updated 30 November 2023
What this trial tests

trial testing Blood in Amyotrophic Lateral Sclerosis in 1,000 participants. Completed in 15 May 2023.

Timeline
30 April 2021
Primary endpoint
31 March 2022
15 May 2023

Quick facts

Lead sponsorUniversity Hospital, Tours
StatusCompleted
Study typeOBSERVATIONAL
Enrollment1,000
Start date30 April 2021
Primary completion31 March 2022
Estimated completion15 May 2023
Sites20 locations across France

Drugs / interventions tested

Conditions studied

Sponsor

University Hospital, Tours

Who can join

18 and older, any sex, with Amyotrophic Lateral Sclerosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of the study is to determine the frequency of mutations in the C9orf72 and SOD1 genes in the incident population of ALS patients followed in the FILSLAN centres

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Blood

Trials testing the same drug.

Other recruiting trials for Amyotrophic Lateral Sclerosis

Currently open trials in the same condition.

Other University Hospital, Tours trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04819555.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing